Outcomes following three-line vision loss during treatment of neovascular age-related macular degeneration: subgroup analyses from MARINA and ANCHOR
Publisher DOI
PubMed ID
21951567
Abstract
This study aims to assess the impact of continued ranibizumab treatment for neovascular age-related macular degeneration on patients from the MARINA and ANCHOR randomised clinical studies who lost ≥ 3 lines of best-corrected visual acuity (BCVA) at any time during the first year of treatment.
Date Issued
2011
Publication Type
Article
Language(s)
en
Author(s)
Holz, Frank G | |
Korobelnik, Jean-François | |
Lanzetta, Paolo | |
Mitchell, Paul | |
Prünte, Christian | |
Schmidt-Erfurth, Ursula | |
Weichselberger, Andreas | |
Hashad, Yehia |
Additional Credits
Journal
British journal of ophthalmology
Publisher
BMJ Publishing Group
ISSN
0007-1161
Access(Rights)
metadata.only